Hit enter to search or ESC to close
Home
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
CRV431 Mechanism of Action [Video]
By
Hepion
January 30, 2020
Media Placements
,
Videos
No Comments
Anti-Fibrotic Activity of Hepion Pharmaceuticals’ CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases
February 19, 2020
Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
February 12, 2020
Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study
January 28, 2020
Leave a Reply
Cancel Reply
Name
*
Email
*
Website
Save my name, email, and website in this browser for the next time I comment.
Share
Tweet
Share
Pin
Home
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
